Pyxis Oncology, Inc. Capital Expenditures Incurred but Not yet Paid
Pyxis Oncology, Inc. (PYXS) reported Capital Expenditures Incurred but Not yet Paid of $237.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-03-18
- Pyxis Oncology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was -$2.26M.
- Pyxis Oncology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $2.26M.
- Pyxis Oncology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $3.12M.
- Pyxis Oncology, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $237.00K, a 94.71% decline from fiscal 2022.
- Pyxis Oncology, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $4.48M, a 40618.18% increase from fiscal 2021.
- Pyxis Oncology, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $11.00K, a 60.71% decline from fiscal 2020.
- Pyxis Oncology, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $28.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2023-12-31 | $237.00K 10-K · filed 2025-03-18 | |||
| 2023-06-30 | -$2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $3.00K 10-Q · filed 2023-08-11 | $3.12M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2023-03-31 | $2.26M 10-Q · filed 2024-05-14 | $5.38M derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.48M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $1.36M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $11.00K 10-K · filed 2023-03-22 | |||
| 2020-12-31 | $28.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |